RICHMOND, Va., January 14, 2026 – Phlow Corp., a leading American pharmaceutical contract development and manufacturing organization (CDMO), today announced a major advancement in AI-driven Active ...

Technological innovations throughout the past several decades have transformed the pharmaceutical manufacturing process from traditional batch production to ...

Enveda has been using AI to power its drug discovery platform for several years. The company injected $230 million into ...

The track by which API manufacturing processes are prepared for commercial use is comparable to overlapping integrative process evaluations at commercial scale. This ensures the process is ...

Given the complexity of alternative-protein manufacturing, many biotech companies are exploring how to reduce costs with AI technologies, process improvements and novel uses for waste streams from ...

Being Proactive Instead of Passive Is the Cornerstone of Process Analytical Technology Interest in the application of process analytical technology (PAT) to pharma and biotech stems from the ...

Under the agreement, Northway Biotech will leverage its expertise in biologics manufacturing to develop the production process for the recombinant sCD83 protein for large-scale production, utilizing ...

MaxCyte, Inc. and Oribiotech Ltd. have announced a strategic collaboration to improve efficiency and scalability in cell therapy manufacturing. This partnership will integrate MaxCyte's ExPERT™ ...

iTOL-100 technology has broad applicability and can be applied to both allogenic and stem cell-derived organoids across a number of diseases Manufacturing agreement supports advancement of ...

Leveraging Northway Biotech's 20+ years of CDMO expertise, Diorasis Therapeutics is advancing DT003, a single-dose AAV gene therapy for glaucoma. As part of the collaboration, Northway Biotech will ...

DUBLIN, Ireland, Dec. 18, 2024 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), a commercial-stage biotechnology company focused on human diagnostics and diabetes management solutions, ...

Nurix Therapeutics has had a phase 1 trial of its B-cell malignancy drug put on partial hold by the FDA while the biotech revamps its manufacturing process. The hold follows the company alerting the ...